

AMNINDER KAUR

Registered Valuer- Securities or Financial Assets

IBBI Regd. No.: IBBI/RV/03/2021/14025

VALUATION REPORT

OF

EIKO LIFESCIENCES LIMITED
CIN: L65993MH1977PLC258134

As on: 8th December, 2025
(Relevant Date)

Date of Issue: 10.12.2025

Place: Ludhiana

Prepared by:
Amninder Kaur

Registered Valuer – Securities or Financial Assets
IBBI Regd. No.: IBBI/RV/03/2021/14025

Address: 69, Phase 3, SKS Nagar, Ludhiana-141013 (Punjab)

Contact: +91 89688 83634

Email: cs.kauramninder@gmail.com

Date: 10.12.2025

To,

The Board of Directors,
Eiko Lifesciences Limited,
CIN: L65993MH1977PLC258134
604, Centrum, Opp. TMC Office Near Satkar Grande Hotel,
Wagle Estate, Thane, Maharashtra, India, 400604

Ref: Valuation Report of Eiko Lifesciences Limited, (“Company”) as on December 08, 2025 for determining Floor Price of Equity Shares.

In reference to the valuation of equity shares (the “Shares”) of, (the “Company”), Ms. Amninder Kaur, Registered Valuer-Securities and Financial Assets having registration no. IBBI/RV/03/2021/14025 (the “Valuer”) has been appointed by the Company to arrive at the Floor Price for Preferential Allotment of Equity Shares.

This cover letter is intended to provide you with an overview of the purpose and scope of our analysis and our conclusion. Please refer to the attached report and presentation of the analysis performed in connection with this engagement.

Purpose and Scope

Based on our discussion with the Management, we understand that the purpose of this valuation engagement is to arrive at the Floor Price of Equity Shares of the Company listed on Recognized Stock Exchange for the purpose of further issue of shares by way of Preferential Allotment in conformity with Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR), as amended from time to time.

The report has been prepared exclusively for specified purpose as mentioned above and hence should not be used for any other purpose, without obtaining the prior written consent from the valuer. In the event, the Company or its management or its representatives intend to extend the use of this report beyond the purples mentioned, with or without consent, we will not accept any responsibility to any party who uses this report or to whom this report may be shown or who may acquire the report. This opinion should not be considered, in whole or in part, as an investment advice by anyone.

Summary of Findings

Based on the assumptions and limiting conditions as described in the report I conclude that:

| Fair Value as per Reg 166A of ICDR Regulations | | | |
|---|---|------------------|--------------------------------|
| Method of Valuation | Value of per Equity Share (in Rs.) | Weightage | Weighted Value (in Rs.) |
| Asset Approach (A) | 40.97 | 10% | 4.10 |

| | | | |
|--|-------|-----|---------------|
| PECV (B) | 6.05 | 10% | 0.61 |
| Weighted Average Price (C) | 50.30 | 80% | 40.24 |
| Fair Value of Equity Share (A+B+C) | | | 44.94 |
| Fair Value as per Reg. 166A (D) (Rounded Off) | | | Rs. 45 |

| Fair Value as per Reg 164 of ICDR Regulations | Source : BSE Data |
|--|--------------------------|
| 90 trading days' Value | Rs. 5,39,16,816 |
| 90 trading days' Volume | 980,681 |
| 10 trading days' Value | Rs. 40,81,248 |
| 10 trading days' Volume | 79,612 |
| 90 trading days' Volume Weighted Average Price (E) | Rs. 54.98 |
| 10 trading days' Volume Weighted Average Price (F) | Rs. 51.26 |
| Value as per Reg. 164 (Higher of (E) or (F) above) | Rs. 54.98 |
| Fair Value as per Reg 164 (G) (Rounded Off) | Rs. 55 |

| | Per Share Value (In Rs.) |
|--|-------------------------------------|
| Fair Value of Equity Shares as per Regulation 166A of ICDR Regulations - (D) | 45 |
| Fair Value of Equity Shares as per Regulation 164 of ICDR Regulations - (G) | 55 |
| Minimum Price at which shares can be issued (Higher of D or G above) | Rs. 55 |

A detailed report along with the annexure for valuation under Regulation 166 A and Regulation 164 of ICDR is appended herewith.



(Amninder Kaur)

Registered Valuer-SFA

IBBI Regd No.: IBBI/RV/03/2021/14025

Place: Ludhiana

Table of Contents

| S. No. | Content |
|---------------|---|
| 1 | Company Overview |
| 2 | Engagement Overview and Appointing Authority |
| 3 | Background of the information |
| 4 | Identity of the Valuer |
| 5 | Disclosure of Interest or Conflict, if any |
| 6 | Date of Appointment, Valuation Date and Date of Report |
| 7 | Nature and Sources of Data/Information used or relied upon |
| 8 | Procedures adopted in carrying out the valuation and Valuation Approach and Methodology |
| 9 | Restrictions on the use of the Report |
| 10 | Caveats, Limitations and Disclaimers |
| | Annexure |

1. Company Overview

A. Master Data

| | | | |
|-----|---|---|--|
| 1. | Subject Company's Name | : | EIKO LIFESCIENCES LIMITED |
| 2. | CIN | : | L65993MH1977PLC258134 |
| 3. | Constitution | : | Public Limited Company |
| 4. | Registered Office | : | 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane, Thane, Maharashtra, India, 400604 |
| 5. | Address other than R/o where all or any books of accounts and papers are maintained | : | |
| 6. | Email | : | investor.relations@eikolifesciences.com |
| 7. | Year of Incorporation | : | 1977 |
| 8. | Authorized Capital (IN INR) | : | 20,00,00,000 |
| 9. | Paid Up Capital (IN INR) | : | 13,72,08,540 |
| 10. | Purpose | : | Determination of Fair Value of Equity Shares for the purpose of Preferential Allotment. |

2. Engagement Overview

a) Purpose of Valuation and Appointing Authority:

The purpose of this valuation engagement is to arrive at the Floor Price of the Equity Shares of the Company for the purpose of further issue of shares by way of Preferential Allotment in accordance with the provisions of regulation 166A of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR) read with regulation 164 of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR), as amended from time to time.

Appointing Authority: Audit Committee of M/s Eiko Lifesciences Limited vide Board Resolution dated 8th December, 2025 duly signed by Mr. Laxmikant Kabra, Director, holding DIN: 00061346.

b) Value Definition:

Business Valuation can be undertaken in a variety of contexts and for variety of purposes. To begin with any valuation purpose, it is most pertinent to identify the type of value relevant to the transaction/ case as different standards of value would yield different valuation figure for same business interest.

c) Basis of Valuation:

According to IVS 104.10.1 Bases of Value (sometimes called standards of value) describe the fundamental premises on which the reported values will be based. It is critical that the basis (or bases) of value be appropriate to the terms and purpose of the valuation assignment, as the basis of value may influence or dictate valuer's selection of methods, inputs and assumptions, and the ultimate opinion of value.

IVS 104.20.1 (a) provides us with the following IVS defined bases of value:

Market Value (section 30),
Market Rent (Section 40),
Equitable Value (section 50),
Investment Value/ Worth (section 60),
Synergistic Value (section 70) and
Liquidation Value (section 80)

IVS 104.20.1 (b) (1) Fair Value (International Financial Reporting Standards) (section 90).

According to IVS 104.20.2 *Valuers* must choose the relevant basis (or bases) of *value* according to the terms and *purpose of the valuation* assignment. The *valuer's* choice of a basis (or bases) of value *should* consider instructions and input received from the *client* and/or its representatives.

In this case, the client has specifically assigned the job to the valuer to estimate the fair value of the equity shares for determining floor price for the purpose of preferential allotment of Equity Shares.

Therefore, the relevant basis of value of this assignment should be "Fair Market Value" which is identical to the Market Value basis as defined in the International Valuation Standards. The present valuation of the Company is undertaken on a Going Concern premise.

3. Background of the Information:

a) Company Overview:

Eiko Lifesciences Limited is a publicly listed specialty chemicals and pharmaceutical intermediates manufacturing company based in Maharashtra, India. Established in 1977 and renamed as Eiko Lifesciences Limited in 2021, the company develops and supplies high-value fine chemicals, organic and inorganic intermediates, and active

pharmaceutical ingredient (API) components serving industries such as pharmaceuticals, agrochemicals, aroma and flavors, cosmetics, and electronic chemicals. With an R&D-driven approach supported by modern laboratory and pilot-scale facilities, Eiko focuses on custom synthesis, quality-controlled production and export-oriented supply from its manufacturing facility in MIDC, Badlapur. The company is listed on the Bombay Stock Exchange and is positioned as an emerging niche player in the specialty chemicals and life-science ingredients sector.

Capital Structure of the Company (As per MCA database)

| Particulars | No. of Shares | Amount (in Rs.) |
|---|---------------|-----------------|
| Authorized Capital | | |
| Equity Shares of Rs. 10/- each | 2,00,00,000 | 20,00,00,000 |
| | | |
| Issued, Subscribed and Paid-up capital | | |
| Equity Shares of Rs. 10/- each | 1,37,20,854 | 13,72,08,540 |

Shareholding Pattern as per latest shareholding pattern filed with BSE:

| Sr. No. | Details of Shareholding | No. of shares held | Percentage Shareholding |
|---------|-----------------------------|--------------------|-------------------------|
| 1 | Promoter and Promoter Group | 50,99,788 | 37.17 |
| 2 | Public | 86,21,066 | 62.83 |
| | Total | 1,37,20,854 | 100.00 |

Directors and Key Managerial Personnel of the Company:

| Sr. No | DIN/PAN | Name | Designation | Date of Appointment |
|--------|------------|---------------------------|---------------------|---------------------|
| 1 | 03353445 | Bhavesh Dhirajlal Tanna | Director | 26/08/2013 |
| 2 | 10977198 | Sumukh Prabhakar Vartak | Whole-time director | 29/07/2025 |
| 3 | 07058562 | Kajal Dhanpatraj Kothari | Director | 09/09/2020 |
| 4 | 05164182 | Rajkumar Govindas Baheti | Director | 10/02/2021 |
| 5 | 00061346 | Laxmikant Ramprasad Kabra | Director | 26/08/2013 |
| 6 | 10757758 | Hasti Arjav Doshi | Director | 03/09/2024 |
| 7 | *****3762E | Jaid Ismail Kojar | CFO | 09/02/2022 |
| 8 | *****2670G | Chintan Bharatbhai Doshi | Company Secretary | 08/11/2023 |

4. Identity of the Valuer

| | | | |
|----|--------------------|---|--|
| 1. | Name of the Valuer | : | Ms. Amninder Kaur |
| 2. | Address | : | 69, Phase 3, SKS Nagar, Ludhiana-141013. |
| 3. | Contact Details | : | Mobile: 89688-83634 Email: cs.kauramninder@gmail.com |
| 4. | Credentials | : | ICSI Registered Valuer (ICSI RVO/COP/SFA0620/197) |
| 5. | Qualifications | : | B. Com, PGDIM, CS, IBBI Qualified Registered Valuer. |

5. Disclosure of Interest or Conflict, if any

The Valuer or any of her relative or associate is not related or associated with the subject company. The Valuer has conducted the valuation independent of external influences.

6. Date of Appointment, Valuation Date and Date of Report

Date of Appointment : December 08, 2025.
 Valuation Date : December 08, 2025.
 Date of Report : December 10, 2025.

7. Nature and Sources of Data/ Information used or relied upon

Nature of underlying data : Primary Data
 Source of data : As provided by Company's Management and data available on BSE and MCA
 Quality of Underlying Data : Dependable

Documents/ Information used or relied upon:

- Published Audited Financial Statements of Eiko Lifesciences Limited for the FY 2025, 2024 and 2023.
- Latest shareholding pattern of the Company available on BSE.
- Annual Report of the Company.
- Trading data from BSE for computing Volume Weighted Average Prices of 90 days and 10 days preceding the relevant date.
- SEBI Pricing guidelines as per ICDR Regulations, 2018.
- Other business-related information and explanations given during the process of valuation as was required for filling gaps.

- g) Reliance has been placed on the verbal explanations and information given to us by the management.
- h) Management Representation Letter.

8. Procedure adopted in carrying out the valuation and Valuation Approach and Methodology

a) Procedure adopted

- i. Receipt of intimation of about appointment and acceptance of proposal.
- ii. Execution of valuation engagement letter and providing checklist of the required documents.
- iii. Receipt of the documents as per the checklist leading to primary study including business analysis.
- iv. Collection of additional documents.
- v. Determining valuation methods and approach.
- vi. Report preparation and its validation.

b) Valuation Standard Followed: International Valuation Standards issued by International Valuation Standards Council (IVSC) and guidance note on valuation issued by the ICSI Registered Valuers Organization have been followed.

c) Valuation approaches and Methodology used:

Valuation of a business is not an exact science and ultimately depends upon what is worth to a serious investor or buyer who may be prepared to pay a substantial goodwill. This exercise may be carried out using various methodologies, the relative emphasis of each varying with:

- Whether the entity is listed on a stock exchange
- Industry to which the company belongs
- Past track record of the business and the ease with which the growth rate in cash flows to perpetuity can be estimated
- Extent to which industry and comparable company information is available

The result of this exercise could vary significantly depending upon the basis used, the specific circumstances and professional judgment of the valuer. In respect of going concerns, certain valuation techniques have evolved over time and are commonly in vogue. These approaches can be broadly categorized as follows:

1. Cost Approach
2. Income Approach
3. Market Approach

Cost Approach

The Cost Approach provides an indication of *value* using the economic principle that a buyer will pay no more for an *asset* than the cost to obtain an *asset* of

equal utility, whether by purchase or by construction, unless undue time, inconvenience, risk or other factors are involved. The approach provides an indication of *value* by calculating the current replacement or reproduction cost of an *asset* and making deductions for physical deterioration and all other relevant forms of obsolescencies. This valuation technique is based on the value of underlying net assets of the business, either on a book value basis or realizable value basis or replacement cost basis. Examples of situations where a valuer applies the cost approach are:

- an asset can be quickly recreated with substantially the same utility as the asset to be valued;
- in case where liquidation value is to be determined; or
- income approach and/or market approach cannot be used

The following are the most commonly used valuation methods under the Cost approach:

- Replacement Cost Method
- Reproduction Cost Method
- Net Asset Method

In the present case, future earnings are not completely based on underlying assets. Therefore, we given 10% weightage to this method of valuation.

Valuation under NAV Approach (Based on Consolidated Financials as on 31st March, 2025)

| Particulars | Amount (in Rs. Lakhs) |
|---|-----------------------|
| Equity Share Capital | 1376.27 |
| Other Equity | 4302.58 |
| Net Asset Value | 5678.85 |
| No. of Equity Shares of Rs. 10 each | 13860445 |
| Net Value of Equity Share in Rs. | 40.97 |
| Net Value of Equity Share in Rs. (Rounded Off) | 41.0 |

Income Approach

The income approach is widely used for valuation under “Going Concern” basis. It focuses on the income generated by the Company in the past as well as its future earning capability. The discount or capitalization rate converts the stream of benefits into present value. There are several different income approaches, including Capitalization of Earnings or Cash Flows, Discounted Future Cash Flows (“DCF”). Under the DCF Method, the business is valued by discounting its free cash flows for the explicit forecast period and the perpetuity value thereafter. The free cash flows in the explicit period and those in perpetuity are discounted by the Weighted Average Cost of Capital (WACC). The WACC based on an optimal viz a viz actual capital structure, is an appropriate rate of discount to calculate the present value of the future cash

flows. The perpetuity value is calculated based on the business potential for future growth beyond the explicit forecast period.

DCF method will require sharing of projections by the Company which is likely to include unpublished price sensitive information. Therefore, this method is not used for valuation.

Instead of DCF, we have used Profit earning Capacity Value Method (PECV) under Income Approach, which discounts the maintainable profits-earning capacity by capitalization rate to ascertain the value.

Based on Standalone Audited Financials as on 31st March 2024-25, 2023-24 and 2022-23.

| Particulars | 2024-25 | 2023-24 | 2022-23 | Amount (in Rs. Lakhs) |
|---|---------|---------|---------|-----------------------|
| Revenue from Operations | 3249.18 | 2792.93 | 1832.14 | |
| Profit before Tax | 231.82 | 98.42 | 106.62 | |
| Weights | 3 | 2 | 1 | 6 |
| Product | 695.46 | 196.84 | 106.62 | 998.92 |
| Weighted Average Profit before tax | | | | 166.49 |
| Taxes @ 25.17% | | | | 41.90 |
| Future Maintainable Profit | | | | 124.58 |
| Capitalization Rate @ 15%* | | | | 830.55 |
| Based on CCI guidelines | | | | |
| No. of Equity Shares | | | | 137.21 |
| Fair Value as per PECV Method (Rounded Off) In INR | | | | 6.05 |

Market Approach

Market Price Method

The market price of a equity share quoted on a stock exchange is normally considered as the value of Equity Share of the company, if such shares are frequently traded. Equity shares of Eiko Lifesciences Limited are listed and traded on BSE and are frequently traded.

Hence, keeping in mind the purpose of valuation we have considered this method for the valuation with 80% weightage.

Weighted Average Price of the date preceding the relevant date (8th December, 2025) as on 5th December, 2025 is Rs. 50.30 and is taken as Fair Value of Equity share (6th and 7th December being Saturday and Sunday).

Comparable Company Multiples Method

The value of a business is determined by comparing the company's accounting ratios with other companies of the same nature and size. This approach is used, where the value of a stock is estimated based upon its current price relative to variable considered to be significant to valuation, such as earnings, cash flow, book value, or sales of various business of the same nature. Business appraisal includes comparative transaction method and publicly traded company method. Through this, it derives a relationship between performance, revenues and selling price.

Extract of pricing provisions of SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018:

Regulation 166 A. (1) Any preferential issue, which may result in a change in control or allotment of more than five percent of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price

Regulation 164. (1) If the equity shares of the issuer have been listed on a recognised stock exchange for a period of 90 trading days or more as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following:

- a) the 90 trading days' volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date; or
- b) the 10 trading days' volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

Regulation 161 For the purpose of this Chapter, "relevant date" means:

- a) in case of preferential issue of equity shares, the date thirty days prior to the date on which the meeting of shareholders is held to consider the proposed preferential issue i.e. **December 08, 2025**.

Opinion on the Valuation:

| Fair Value as per Reg 166A of ICDR Regulations | | | |
|--|------------------------------------|-----------|-------------------------|
| Method of Valuation | Value of per Equity Share (in Rs.) | Weightage | Weighted Value (in Rs.) |
| Asset Approach (A) | 40.97 | 10% | 4.10 |
| PECV (B) | 6.05 | 10% | 0.61 |

| | | | |
|--|-------|-----|---------------|
| Weighted Average Price (C) | 50.30 | 80% | 40.24 |
| Fair Value of Equity Share (A+B+C) | | | 44.94 |
| Fair Value as per Reg. 166A (D) (Rounded Off) | | | Rs. 45 |

Valuation under Regulation 164 of ICDR Regulations has been arrived at by considering data between 28th July, 2025 to 5th December, 2025, (90 trading days) as follows:

| Fair Value as per Reg 164 of ICDR Regulations | Source : BSE Data |
|--|--------------------------|
| 90 trading days' Value | Rs. 5,39,16,816 |
| 90 trading days' Volume | 980,681 |
| 10 trading days' Value | Rs. 40,81,248 |
| 10 trading days' Volume | 79,612 |
| 90 trading days' Volume Weighted Average Price (E) | Rs. 54.98 |
| 10 trading days' Volume Weighted Average Price (F) | Rs. 51.26 |
| Value as per Reg. 164 (Higher of (E) or (F) above) | Rs. 54.98 |
| Fair Value as per Reg 164 (G) (Rounded Off) | Rs. 55 |

Shares of the Company are frequently traded and the trading data has been annexed to this report as **Annexure I**.

| | Per Share Value (In Rs.) |
|--|-------------------------------------|
| Fair Value of Equity Shares as per Regulation 166A of ICDR Regulations - (D) | 45 |
| Fair Value of Equity Shares as per Regulation 164 of ICDR Regulations - (G) | 55 |
| Minimum Price at which shares can be issued (Higher of D or G above) | Rs. 55 |

As per the valuation methodologies Fair Value of equity share of the Company is determined at Rs. 45.00 per share. However, floor price as per minimum pricing guidelines specified in regulation 164 and regulation 166A of ICDR Regulations is Rs. 55.00 per share.

9. Restrictions on the use of the Report

This report is subject to the scope, assumptions, exclusions, caveats, limitations and disclaimers detailed hereinafter in Point No. 10. As such, the report is to be read in totality, and not in parts, in conjunction with the relevant documents referred to herein and specifically used for the purpose mentioned in the report.

10. Caveats, Limitations and Disclaimers

a. Purpose and Scope

This valuation report has been prepared solely for the specific purpose outlined in the report and is valid only as of the valuation date. It does not constitute an offer or recommendation to buy or sell any securities, nor does it confirm or opine on any proposed transaction structure.

This report is intended to be read in its entirety and in conjunction with supporting documents, and should not be used or relied upon in isolation.

The analysis and opinions herein are based on information provided by the management of the Company, as well as publicly available and other relevant sources. No independent verification or audit of such information has been conducted by us.

b. Reliance on Information and Representations

We have relied upon financial, operational, and other data provided by the management. The accuracy, reliability, and completeness of such information are the responsibility of the Company. Our conclusions are contingent upon the assumptions that the data provided is materially correct.

No due diligence or forensic review was undertaken as part of this assignment. We have not investigated the title of the assets, existence of encumbrances, or any legal claims or litigations. We have received confirmation that there are no events, demands, or legal or other decisions pending against the Company that could materially impact the financial position as of the valuation date or the future profitability of the Company.

Forecasts and projections provided by management have been assumed to be reasonable, but we do not provide assurance on their achievability. The valuation is sensitive to the assumptions made by the management and any material deviation may impact the outcome.

c. Methodology and Judgement

Valuation is not an exact science and involves significant professional judgment. Various external factors, including market sentiment, competition, management effectiveness, and broader economic conditions, may materially influence valuation conclusions.

Different valuers may adopt different assumptions leading to different value outcomes. The conclusions of this report represent a professional opinion based on prevailing conditions and available data.

d. Limitations of Use

This report is confidential and intended only for the use of the appointing authority and regulatory bodies as required. It must not be shared, quoted, or disclosed without prior written consent, except where required under applicable laws.

No part of this report should be interpreted as legal, accounting, or tax advice. Separate expert advice must be sought for such matters. The valuation does not assess the commercial rationale or comparative merits of any proposed transaction.

e. Liability and Legal Considerations

We accept no liability to any third party for unauthorized use of this report. The responsibility for the final transaction decision lies solely with the Board of Directors or approving authority.

We shall not be liable for any loss arising from fraudulent acts, misrepresentations, or omissions on the part of the Company, its directors, or any other stakeholders.

Class action suits, as contemplated under international legal frameworks, are not applicable to Registered Valuers operating under the regulatory framework of the Companies Act, 2013 and the rules prescribed thereunder in India. Accordingly, no liability whether collective or otherwise shall arise against the undersigned Valuer in the nature of a class action. Any claims, if any, shall be governed strictly by Indian law and shall be subject to the terms of the engagement and applicable legal remedies under Indian jurisdiction only.

This report is subject to Indian law and may be disclosed to regulatory authorities if required. The fees for this engagement are not contingent on the valuation outcome.

Annexure I

| Trading Days | Date | Open Price | High Price | Low Price | WAP | No. of Shares | Total Turnover (Rs.) |
|--------------|-----------|------------|------------|-----------|------|---------------|----------------------|
| 1 | 05-Dec-25 | 51.69 | 51.69 | 50.12 | 50.3 | 5180 | 260312 |
| 2 | 04-Dec-25 | 51 | 51.7 | 50.51 | 50.6 | 2099 | 106222 |
| 3 | 03-Dec-25 | 51.9 | 52.45 | 50.68 | 51.1 | 4032 | 206021 |
| 4 | 02-Dec-25 | 51.9 | 51.9 | 50.26 | 50.9 | 6372 | 324534 |
| 5 | 01-Dec-25 | 52.3 | 52.3 | 50.5 | 51.1 | 18891 | 965019 |
| 6 | 28-Nov-25 | 50.95 | 52.38 | 50.95 | 51.5 | 4576 | 235499 |
| 7 | 27-Nov-25 | 52 | 52 | 50 | 50.8 | 12894 | 654688 |
| 8 | 26-Nov-25 | 51.65 | 52.88 | 51 | 51.6 | 14670 | 756772 |
| 9 | 25-Nov-25 | 54 | 54 | 51.5 | 52.4 | 7654 | 400997 |
| 10 | 24-Nov-25 | 54.18 | 54.18 | 52.4 | 52.8 | 3244 | 171184 |
| 11 | 21-Nov-25 | 53.08 | 53.86 | 52.5 | 52.7 | 3132 | 165170 |
| 12 | 20-Nov-25 | 54.03 | 54.88 | 52.57 | 53.1 | 1521 | 80775 |
| 13 | 19-Nov-25 | 52.22 | 54.98 | 52.22 | 54.1 | 1121 | 60611 |
| 14 | 18-Nov-25 | 53.99 | 54.5 | 52.21 | 54.1 | 2849 | 154041 |
| 15 | 17-Nov-25 | 56.49 | 56.49 | 52.68 | 53.6 | 21095 | 1129899 |
| 16 | 14-Nov-25 | 53.31 | 56 | 53.31 | 54.1 | 7749 | 419444 |
| 17 | 13-Nov-25 | 55.9 | 55.9 | 54 | 54.6 | 13209 | 721010 |
| 18 | 12-Nov-25 | 55.99 | 55.99 | 54 | 54.7 | 3852 | 210735 |
| 19 | 11-Nov-25 | 55.5 | 57.8 | 54.12 | 55.2 | 14265 | 786912 |
| 20 | 10-Nov-25 | 55.9 | 57.99 | 55.01 | 56.8 | 15199 | 862748 |
| 21 | 07-Nov-25 | 58.98 | 58.98 | 53.32 | 55.4 | 21063 | 1167719 |
| 22 | 06-Nov-25 | 64.25 | 64.25 | 57.03 | 58.5 | 33919 | 1982980 |
| 23 | 04-Nov-25 | 59.9 | 64.44 | 56.51 | 62.4 | 122956 | 7669996 |
| 24 | 03-Nov-25 | 58 | 60.5 | 57.05 | 58.9 | 45145 | 2659291 |
| 25 | 31-Oct-25 | 52.65 | 57.99 | 52.65 | 54.8 | 42053 | 2303366 |
| 26 | 30-Oct-25 | 51.49 | 52.99 | 50.02 | 51.6 | 11497 | 593478 |
| 27 | 29-Oct-25 | 51.99 | 51.99 | 50 | 50.9 | 11092 | 564190 |
| 28 | 28-Oct-25 | 51.44 | 52.55 | 50.21 | 51.7 | 3662 | 189325 |
| 29 | 27-Oct-25 | 50 | 52 | 49.99 | 50.9 | 8989 | 457915 |
| 30 | 24-Oct-25 | 51.19 | 52.65 | 49.86 | 50.3 | 15271 | 768048 |
| 31 | 23-Oct-25 | 54.49 | 54.6 | 51 | 51.5 | 6145 | 316420 |
| 32 | 21-Oct-25 | 50.95 | 52.99 | 50.94 | 51.9 | 1438 | 74620 |
| 33 | 20-Oct-25 | 54.9 | 54.9 | 50 | 50.7 | 3339 | 169361 |
| 34 | 17-Oct-25 | 52.99 | 53 | 50.5 | 50.8 | 6860 | 348331 |
| 35 | 16-Oct-25 | 51.43 | 51.77 | 50.7 | 51.6 | 1580 | 81528 |
| 36 | 15-Oct-25 | 51.22 | 51.78 | 50 | 50.4 | 8159 | 410951 |
| 37 | 14-Oct-25 | 52 | 52.54 | 50.4 | 51.2 | 5396 | 276531 |
| 38 | 13-Oct-25 | 51.21 | 52.8 | 51.21 | 51.7 | 1365 | 70618 |
| 39 | 10-Oct-25 | 52.1 | 52.84 | 51.55 | 52 | 4062 | 211119 |

| | | | | | | | |
|----|-----------|-------|-------|-------|------|-------|---------|
| 40 | 09-Oct-25 | 51.71 | 52.89 | 51.21 | 52.1 | 6638 | 345535 |
| 41 | 08-Oct-25 | 51.21 | 52.24 | 51.18 | 51.8 | 2939 | 152345 |
| 42 | 07-Oct-25 | 51.17 | 53.1 | 51.01 | 52 | 4987 | 259425 |
| 43 | 06-Oct-25 | 52 | 53.44 | 51.01 | 51.5 | 11708 | 603089 |
| 44 | 03-Oct-25 | 52.01 | 53.9 | 51.56 | 52.2 | 8206 | 428229 |
| 45 | 01-Oct-25 | 53.25 | 53.5 | 51.71 | 52.2 | 566 | 29561 |
| 46 | 30-Sep-25 | 52.4 | 53.4 | 51.52 | 52.7 | 5745 | 302699 |
| 47 | 29-Sep-25 | 52.16 | 53.47 | 51.36 | 52.2 | 8432 | 440097 |
| 48 | 26-Sep-25 | 52.22 | 53.79 | 52.2 | 52.7 | 3950 | 208187 |
| 49 | 25-Sep-25 | 53 | 54 | 52.25 | 52.9 | 9704 | 513761 |
| 50 | 24-Sep-25 | 56.48 | 56.48 | 53.62 | 54 | 478 | 25820 |
| 51 | 23-Sep-25 | 55.24 | 55.24 | 53.71 | 54.6 | 3832 | 209132 |
| 52 | 22-Sep-25 | 54 | 56 | 53.11 | 54.6 | 12977 | 708013 |
| 53 | 19-Sep-25 | 55.85 | 57.89 | 54.27 | 55.2 | 1811 | 99968 |
| 54 | 18-Sep-25 | 55.99 | 55.99 | 53.58 | 54.8 | 1389 | 76126 |
| 55 | 17-Sep-25 | 55.94 | 56.5 | 53.51 | 54.6 | 8733 | 476604 |
| 56 | 16-Sep-25 | 55 | 56.48 | 54.3 | 55.3 | 1494 | 82620 |
| 57 | 15-Sep-25 | 54.75 | 55.97 | 54.7 | 54.9 | 1629 | 89509 |
| 58 | 12-Sep-25 | 56.29 | 57.65 | 53.5 | 55.7 | 17304 | 964375 |
| 59 | 11-Sep-25 | 56.98 | 57.78 | 55.14 | 56.4 | 1618 | 91289 |
| 60 | 10-Sep-25 | 53.99 | 57.9 | 53.45 | 55.9 | 23830 | 1332786 |
| 61 | 09-Sep-25 | 54.49 | 54.49 | 52 | 52.2 | 18410 | 960314 |
| 62 | 08-Sep-25 | 50.56 | 54.99 | 50.56 | 53.4 | 28489 | 1521871 |
| 63 | 05-Sep-25 | 52.3 | 52.3 | 51.11 | 51.4 | 1459 | 74934 |
| 64 | 04-Sep-25 | 52.02 | 52.02 | 50.75 | 51.2 | 3432 | 175573 |
| 65 | 03-Sep-25 | 52.72 | 52.72 | 51.4 | 51.8 | 9406 | 487053 |
| 66 | 02-Sep-25 | 52.51 | 52.79 | 51.51 | 52.5 | 7692 | 403502 |
| 67 | 01-Sep-25 | 51.05 | 52.4 | 51.04 | 52.1 | 14821 | 771756 |
| 68 | 29-Aug-25 | 53.69 | 53.69 | 51 | 51.7 | 12713 | 656675 |
| 69 | 28-Aug-25 | 53.3 | 53.3 | 51.68 | 52.1 | 10646 | 554535 |
| 70 | 26-Aug-25 | 52 | 53.36 | 52 | 52.3 | 7030 | 367846 |
| 71 | 25-Aug-25 | 53.84 | 53.9 | 52.33 | 53.2 | 4836 | 257113 |
| 72 | 22-Aug-25 | 53.1 | 54 | 51.6 | 53 | 13016 | 689672 |
| 73 | 21-Aug-25 | 53 | 54.39 | 52.57 | 53.4 | 2792 | 148978 |
| 74 | 20-Aug-25 | 53.9 | 53.9 | 53.12 | 53.3 | 5071 | 270092 |
| 75 | 19-Aug-25 | 55 | 55 | 52.76 | 53.3 | 9783 | 520975 |
| 76 | 18-Aug-25 | 55.95 | 55.95 | 53.25 | 54.3 | 1941 | 105488 |
| 77 | 14-Aug-25 | 53.95 | 54.25 | 52.59 | 53.9 | 2762 | 148786 |
| 78 | 13-Aug-25 | 53.21 | 54.89 | 53.21 | 53.8 | 744 | 40010 |
| 79 | 12-Aug-25 | 53.98 | 55 | 52.6 | 54.4 | 2067 | 112434 |
| 80 | 11-Aug-25 | 54.99 | 54.99 | 52.03 | 52.8 | 15707 | 829268 |
| 81 | 08-Aug-25 | 54.09 | 54.9 | 53.5 | 54 | 3880 | 209446 |

AMNINDER KAUR

Registered Valuer- Securities or Financial Assets

IBBI Regd. No.: IBBI/RV/03/2021/14025

| | | | | | | | |
|-------------------|-----------|-------|-------|-------|------|---------|------------|
| 82 | 07-Aug-25 | 55.79 | 55.79 | 53.75 | 54.3 | 8828 | 479415 |
| 83 | 06-Aug-25 | 55.48 | 55.99 | 53.6 | 55 | 8012 | 440527 |
| 84 | 05-Aug-25 | 54.25 | 56 | 53.98 | 54.7 | 15161 | 828778 |
| 85 | 04-Aug-25 | 56.95 | 56.95 | 53 | 54.2 | 13037 | 706958 |
| 86 | 01-Aug-25 | 57.5 | 57.5 | 54.25 | 55.4 | 7481 | 414317 |
| 87 | 31-Jul-25 | 53.5 | 58.4 | 53.5 | 57 | 25527 | 1455355 |
| 88 | 30-Jul-25 | 58.5 | 58.5 | 53.84 | 56.1 | 25915 | 1452846 |
| 89 | 29-Jul-25 | 53.9 | 58.5 | 51.75 | 54.8 | 32444 | 1777637 |
| 90 | 28-Jul-25 | 53.69 | 54.09 | 51.5 | 52.2 | 12014 | 627112 |
| 90 Days' Total | | | | | | 980,681 | 53,916,816 |
| 90 Days' VWAP | | | | 54.98 | | | |
| 10 Days' Total | | | | | | 79,612 | 4,081,248 |
| 10 Days' VWAP | | | | 51.26 | | | |
| Higher out of two | | | | 54.98 | | | |

Frequency of Trading

| Trading Days | Date | Open Price | High Price | Low Price | WAP | No. of Shares | Total Turnover (Rs.) |
|--------------|-----------|------------|------------|-----------|-------|---------------|----------------------|
| 1 | 08-Dec-25 | 51 | 51 | 48 | 49.59 | 16763 | 831246 |
| 2 | 05-Dec-25 | 51.69 | 51.69 | 50.12 | 50.25 | 5180 | 260312 |
| 3 | 04-Dec-25 | 51 | 51.7 | 50.51 | 50.61 | 2099 | 106222 |
| 4 | 03-Dec-25 | 51.9 | 52.45 | 50.68 | 51.10 | 4032 | 206021 |
| 5 | 02-Dec-25 | 51.9 | 51.9 | 50.26 | 50.93 | 6372 | 324534 |
| 6 | 01-Dec-25 | 52.3 | 52.3 | 50.5 | 51.08 | 18891 | 965019 |
| 7 | 28-Nov-25 | 50.95 | 52.38 | 50.95 | 51.46 | 4576 | 235499 |
| 8 | 27-Nov-25 | 52 | 52 | 50 | 50.77 | 12894 | 654688 |
| 9 | 26-Nov-25 | 51.65 | 52.88 | 51 | 51.59 | 14670 | 756772 |
| 10 | 25-Nov-25 | 54 | 54 | 51.5 | 52.39 | 7654 | 400997 |
| 11 | 24-Nov-25 | 54.18 | 54.18 | 52.4 | 52.77 | 3244 | 171184 |
| 12 | 21-Nov-25 | 53.08 | 53.86 | 52.5 | 52.74 | 3132 | 165170 |
| 13 | 20-Nov-25 | 54.03 | 54.88 | 52.57 | 53.11 | 1521 | 80775 |
| 14 | 19-Nov-25 | 52.22 | 54.98 | 52.22 | 54.07 | 1121 | 60611 |
| 15 | 18-Nov-25 | 53.99 | 54.5 | 52.21 | 54.07 | 2849 | 154041 |
| 16 | 17-Nov-25 | 56.49 | 56.49 | 52.68 | 53.56 | 21095 | 1129899 |
| 17 | 14-Nov-25 | 53.31 | 56 | 53.31 | 54.13 | 7749 | 419444 |
| 18 | 13-Nov-25 | 55.9 | 55.9 | 54 | 54.58 | 13209 | 721010 |
| 19 | 12-Nov-25 | 55.99 | 55.99 | 54 | 54.71 | 3852 | 210735 |
| 20 | 11-Nov-25 | 55.5 | 57.8 | 54.12 | 55.16 | 14265 | 786912 |
| 21 | 10-Nov-25 | 55.9 | 57.99 | 55.01 | 56.76 | 15199 | 862748 |
| 22 | 07-Nov-25 | 58.98 | 58.98 | 53.32 | 55.44 | 21063 | 1167719 |
| 23 | 06-Nov-25 | 64.25 | 64.25 | 57.03 | 58.46 | 33919 | 1982980 |
| 24 | 04-Nov-25 | 59.9 | 64.44 | 56.51 | 62.38 | 122956 | 7669996 |
| 25 | 03-Nov-25 | 58 | 60.5 | 57.05 | 58.91 | 45145 | 2659291 |
| 26 | 31-Oct-25 | 52.65 | 57.99 | 52.65 | 54.77 | 42053 | 2303366 |
| 27 | 30-Oct-25 | 51.49 | 52.99 | 50.02 | 51.62 | 11497 | 593478 |
| 28 | 29-Oct-25 | 51.99 | 51.99 | 50 | 50.86 | 11092 | 564190 |
| 29 | 28-Oct-25 | 51.44 | 52.55 | 50.21 | 51.70 | 3662 | 189325 |
| 30 | 27-Oct-25 | 50 | 52 | 49.99 | 50.94 | 8989 | 457915 |
| 31 | 24-Oct-25 | 51.19 | 52.65 | 49.86 | 50.29 | 15271 | 768048 |
| 32 | 23-Oct-25 | 54.49 | 54.6 | 51 | 51.49 | 6145 | 316420 |
| 33 | 21-Oct-25 | 50.95 | 52.99 | 50.94 | 51.89 | 1438 | 74620 |
| 34 | 20-Oct-25 | 54.9 | 54.9 | 50 | 50.72 | 3339 | 169361 |
| 35 | 17-Oct-25 | 52.99 | 53 | 50.5 | 50.78 | 6860 | 348331 |
| 36 | 16-Oct-25 | 51.43 | 51.77 | 50.7 | 51.60 | 1580 | 81528 |
| 37 | 15-Oct-25 | 51.22 | 51.78 | 50 | 50.37 | 8159 | 410951 |
| 38 | 14-Oct-25 | 52 | 52.54 | 50.4 | 51.25 | 5396 | 276531 |
| 39 | 13-Oct-25 | 51.21 | 52.8 | 51.21 | 51.73 | 1365 | 70618 |

| | | | | | | | |
|----|-----------|-------|-------|-------|-------|-------|---------|
| 40 | 10-Oct-25 | 52.1 | 52.84 | 51.55 | 51.97 | 4062 | 211119 |
| 41 | 09-Oct-25 | 51.71 | 52.89 | 51.21 | 52.05 | 6638 | 345535 |
| 42 | 08-Oct-25 | 51.21 | 52.24 | 51.18 | 51.84 | 2939 | 152345 |
| 43 | 07-Oct-25 | 51.17 | 53.1 | 51.01 | 52.02 | 4987 | 259425 |
| 44 | 06-Oct-25 | 52 | 53.44 | 51.01 | 51.51 | 11708 | 603089 |
| 45 | 03-Oct-25 | 52.01 | 53.9 | 51.56 | 52.18 | 8206 | 428229 |
| 46 | 01-Oct-25 | 53.25 | 53.5 | 51.71 | 52.23 | 566 | 29561 |
| 47 | 30-Sep-25 | 52.4 | 53.4 | 51.52 | 52.69 | 5745 | 302699 |
| 48 | 29-Sep-25 | 52.16 | 53.47 | 51.36 | 52.19 | 8432 | 440097 |
| 49 | 26-Sep-25 | 52.22 | 53.79 | 52.2 | 52.71 | 3950 | 208187 |
| 50 | 25-Sep-25 | 53 | 54 | 52.25 | 52.94 | 9704 | 513761 |
| 51 | 24-Sep-25 | 56.48 | 56.48 | 53.62 | 54.02 | 478 | 25820 |
| 52 | 23-Sep-25 | 55.24 | 55.24 | 53.71 | 54.58 | 3832 | 209132 |
| 53 | 22-Sep-25 | 54 | 56 | 53.11 | 54.56 | 12977 | 708013 |
| 54 | 19-Sep-25 | 55.85 | 57.89 | 54.27 | 55.20 | 1811 | 99968 |
| 55 | 18-Sep-25 | 55.99 | 55.99 | 53.58 | 54.81 | 1389 | 76126 |
| 56 | 17-Sep-25 | 55.94 | 56.5 | 53.51 | 54.58 | 8733 | 476604 |
| 57 | 16-Sep-25 | 55 | 56.48 | 54.3 | 55.30 | 1494 | 82620 |
| 58 | 15-Sep-25 | 54.75 | 55.97 | 54.7 | 54.95 | 1629 | 89509 |
| 59 | 12-Sep-25 | 56.29 | 57.65 | 53.5 | 55.73 | 17304 | 964375 |
| 60 | 11-Sep-25 | 56.98 | 57.78 | 55.14 | 56.42 | 1618 | 91289 |
| 61 | 10-Sep-25 | 53.99 | 57.9 | 53.45 | 55.93 | 23830 | 1332786 |
| 62 | 09-Sep-25 | 54.49 | 54.49 | 52 | 52.16 | 18410 | 960314 |
| 63 | 08-Sep-25 | 50.56 | 54.99 | 50.56 | 53.42 | 28489 | 1521871 |
| 64 | 05-Sep-25 | 52.3 | 52.3 | 51.11 | 51.36 | 1459 | 74934 |
| 65 | 04-Sep-25 | 52.02 | 52.02 | 50.75 | 51.16 | 3432 | 175573 |
| 66 | 03-Sep-25 | 52.72 | 52.72 | 51.4 | 51.78 | 9406 | 487053 |
| 67 | 02-Sep-25 | 52.51 | 52.79 | 51.51 | 52.46 | 7692 | 403502 |
| 68 | 01-Sep-25 | 51.05 | 52.4 | 51.04 | 52.07 | 14821 | 771756 |
| 69 | 29-Aug-25 | 53.69 | 53.69 | 51 | 51.65 | 12713 | 656675 |
| 70 | 28-Aug-25 | 53.3 | 53.3 | 51.68 | 52.09 | 10646 | 554535 |
| 71 | 26-Aug-25 | 52 | 53.36 | 52 | 52.33 | 7030 | 367846 |
| 72 | 25-Aug-25 | 53.84 | 53.9 | 52.33 | 53.17 | 4836 | 257113 |
| 73 | 22-Aug-25 | 53.1 | 54 | 51.6 | 52.99 | 13016 | 689672 |
| 74 | 21-Aug-25 | 53 | 54.39 | 52.57 | 53.36 | 2792 | 148978 |
| 75 | 20-Aug-25 | 53.9 | 53.9 | 53.12 | 53.26 | 5071 | 270092 |
| 76 | 19-Aug-25 | 55 | 55 | 52.76 | 53.25 | 9783 | 520975 |
| 77 | 18-Aug-25 | 55.95 | 55.95 | 53.25 | 54.35 | 1941 | 105488 |
| 78 | 14-Aug-25 | 53.95 | 54.25 | 52.59 | 53.87 | 2762 | 148786 |
| 79 | 13-Aug-25 | 53.21 | 54.89 | 53.21 | 53.78 | 744 | 40010 |
| 80 | 12-Aug-25 | 53.98 | 55 | 52.6 | 54.39 | 2067 | 112434 |
| 81 | 11-Aug-25 | 54.99 | 54.99 | 52.03 | 52.80 | 15707 | 829268 |

| | | | | | | | |
|-----|-----------|-------|-------|-------|-------|--------|----------|
| 82 | 08-Aug-25 | 54.09 | 54.9 | 53.5 | 53.98 | 3880 | 209446 |
| 83 | 07-Aug-25 | 55.79 | 55.79 | 53.75 | 54.31 | 8828 | 479415 |
| 84 | 06-Aug-25 | 55.48 | 55.99 | 53.6 | 54.98 | 8012 | 440527 |
| 85 | 05-Aug-25 | 54.25 | 56 | 53.98 | 54.67 | 15161 | 828778 |
| 86 | 04-Aug-25 | 56.95 | 56.95 | 53 | 54.23 | 13037 | 706958 |
| 87 | 01-Aug-25 | 57.5 | 57.5 | 54.25 | 55.38 | 7481 | 414317 |
| 88 | 31-Jul-25 | 53.5 | 58.4 | 53.5 | 57.01 | 25527 | 1455355 |
| 89 | 30-Jul-25 | 58.5 | 58.5 | 53.84 | 56.06 | 25915 | 1452846 |
| 90 | 29-Jul-25 | 53.9 | 58.5 | 51.75 | 54.79 | 32444 | 1777637 |
| 91 | 28-Jul-25 | 53.69 | 54.09 | 51.5 | 52.20 | 12014 | 627112 |
| 92 | 25-Jul-25 | 55.79 | 56 | 50 | 52.61 | 18174 | 956126 |
| 93 | 24-Jul-25 | 55.98 | 57.5 | 52.99 | 54.37 | 22403 | 1218149 |
| 94 | 23-Jul-25 | 57.98 | 57.99 | 53.15 | 55.00 | 23959 | 1317651 |
| 95 | 22-Jul-25 | 56.2 | 61.99 | 55.25 | 59.20 | 42968 | 2543590 |
| 96 | 21-Jul-25 | 57.96 | 57.99 | 54 | 55.84 | 8785 | 490550 |
| 97 | 18-Jul-25 | 52.1 | 60.39 | 52.1 | 57.26 | 48294 | 2765439 |
| 98 | 17-Jul-25 | 55.8 | 55.8 | 52.1 | 52.82 | 11223 | 592789 |
| 99 | 16-Jul-25 | 54 | 54.47 | 53.27 | 53.73 | 1453 | 78068 |
| 100 | 15-Jul-25 | 56 | 57.75 | 53.15 | 54.25 | 30127 | 1634357 |
| 101 | 14-Jul-25 | 56.62 | 56.97 | 54.3 | 55.22 | 4365 | 241020 |
| 102 | 11-Jul-25 | 57.47 | 57.47 | 54.96 | 56.08 | 11610 | 651054 |
| 103 | 10-Jul-25 | 59.5 | 60.99 | 56 | 58.37 | 22072 | 1288242 |
| 104 | 09-Jul-25 | 61 | 61.29 | 59.38 | 59.78 | 5349 | 319773 |
| 105 | 08-Jul-25 | 62.37 | 62.37 | 58.8 | 59.97 | 13016 | 780591 |
| 106 | 07-Jul-25 | 61.21 | 64 | 60.01 | 61.42 | 13760 | 845123 |
| 107 | 04-Jul-25 | 65.49 | 65.49 | 59.42 | 61.97 | 89360 | 5537630 |
| 108 | 03-Jul-25 | 60.25 | 65.9 | 56.2 | 62.42 | 187475 | 11701351 |
| 109 | 02-Jul-25 | 50.74 | 59.71 | 49.56 | 57.26 | 198684 | 11376809 |
| 110 | 01-Jul-25 | 49.56 | 51.42 | 48.21 | 49.74 | 49638 | 2469122 |
| 111 | 30-Jun-25 | 51.45 | 51.45 | 49.02 | 49.80 | 3723 | 185407 |
| 112 | 27-Jun-25 | 50 | 50.9 | 48.55 | 49.80 | 12806 | 637733 |
| 113 | 26-Jun-25 | 49 | 51.05 | 49 | 49.76 | 9836 | 489399 |
| 114 | 25-Jun-25 | 49.97 | 51.4 | 47.99 | 49.20 | 113037 | 5561873 |
| 115 | 24-Jun-25 | 49.96 | 49.96 | 48.7 | 49.07 | 10039 | 492656 |
| 116 | 23-Jun-25 | 50.49 | 50.49 | 48.34 | 48.83 | 16888 | 824572 |
| 117 | 20-Jun-25 | 50.97 | 50.97 | 49.56 | 49.97 | 2633 | 131567 |
| 118 | 19-Jun-25 | 51.27 | 51.27 | 48.5 | 49.84 | 4996 | 248997 |
| 119 | 18-Jun-25 | 51 | 51.8 | 49.61 | 50.78 | 18777 | 953517 |
| 120 | 17-Jun-25 | 51.09 | 51.39 | 49.62 | 50.31 | 10248 | 515531 |
| 121 | 16-Jun-25 | 50.69 | 51.49 | 49.57 | 50.45 | 6982 | 352262 |
| 122 | 13-Jun-25 | 50.9 | 50.9 | 49 | 49.97 | 4276 | 213673 |
| 123 | 12-Jun-25 | 51.99 | 51.99 | 50 | 50.87 | 7129 | 362663 |

| | | | | | | | |
|-----|-----------|-------|-------|-------|-------|-------|---------|
| 124 | 11-Jun-25 | 52.2 | 52.2 | 50.1 | 51.11 | 22231 | 1136177 |
| 125 | 10-Jun-25 | 50.1 | 52.25 | 50 | 50.90 | 21325 | 1085543 |
| 126 | 09-Jun-25 | 50.48 | 50.48 | 49 | 49.72 | 6881 | 342108 |
| 127 | 06-Jun-25 | 50 | 51.84 | 48.52 | 49.68 | 17648 | 876764 |
| 128 | 05-Jun-25 | 51.85 | 51.85 | 49.7 | 50.06 | 9960 | 498553 |
| 129 | 04-Jun-25 | 50.79 | 52.16 | 49.1 | 50.57 | 8688 | 439358 |
| 130 | 03-Jun-25 | 51.45 | 51.45 | 49.57 | 50.40 | 3420 | 172380 |
| 131 | 02-Jun-25 | 49.65 | 51.4 | 49.51 | 49.98 | 3191 | 159493 |
| 132 | 30-May-25 | 53.4 | 53.4 | 49.27 | 50.69 | 25276 | 1281248 |
| 133 | 29-May-25 | 52.06 | 53 | 51.32 | 52.29 | 7631 | 399038 |
| 134 | 28-May-25 | 51.16 | 53.9 | 51.16 | 52.66 | 3042 | 160178 |
| 135 | 27-May-25 | 53 | 53 | 51.51 | 52.36 | 1865 | 97652 |
| 136 | 26-May-25 | 50.97 | 54.94 | 49.5 | 52.63 | 20363 | 1071646 |
| 137 | 23-May-25 | 50.79 | 51.65 | 50.08 | 50.53 | 2996 | 151390 |
| 138 | 22-May-25 | 51.93 | 52.5 | 47.1 | 49.44 | 18911 | 934935 |
| 139 | 21-May-25 | 50.34 | 53.7 | 50 | 51.98 | 17983 | 934767 |
| 140 | 20-May-25 | 52.99 | 52.99 | 49.67 | 51.00 | 11879 | 605770 |
| 141 | 19-May-25 | 52.95 | 52.95 | 49 | 50.76 | 7153 | 363088 |
| 142 | 16-May-25 | 53.19 | 53.19 | 50.61 | 51.30 | 3870 | 198537 |
| 143 | 15-May-25 | 53 | 53.66 | 51.26 | 52.19 | 17501 | 913345 |
| 144 | 14-May-25 | 50.48 | 51.9 | 48.75 | 50.53 | 21477 | 1085238 |
| 145 | 13-May-25 | 50.99 | 50.99 | 48.9 | 49.56 | 15641 | 775104 |
| 146 | 12-May-25 | 49.96 | 52 | 49 | 50.05 | 4777 | 239073 |
| 147 | 09-May-25 | 48.65 | 48.89 | 47.26 | 48.36 | 2004 | 96914 |
| 148 | 08-May-25 | 50.15 | 51.64 | 48 | 49.37 | 12424 | 613320 |
| 149 | 07-May-25 | 47.05 | 50.67 | 47.05 | 48.34 | 850 | 41085 |
| 150 | 06-May-25 | 49.98 | 49.98 | 48.5 | 49.13 | 4334 | 212909 |
| 151 | 05-May-25 | 50.03 | 53.8 | 48 | 49.73 | 10578 | 526085 |
| 152 | 02-May-25 | 52 | 52.48 | 49.5 | 50.32 | 5748 | 289221 |
| 153 | 30-Apr-25 | 52.3 | 56 | 49.99 | 51.82 | 16256 | 842386 |
| 154 | 29-Apr-25 | 53.85 | 53.85 | 51.21 | 52.36 | 3737 | 195656 |
| 155 | 28-Apr-25 | 54.49 | 54.49 | 51 | 52.23 | 13260 | 692537 |
| 156 | 25-Apr-25 | 52.98 | 52.98 | 49.43 | 50.51 | 10631 | 536961 |
| 157 | 24-Apr-25 | 52.12 | 53.47 | 51.21 | 51.78 | 16666 | 862908 |
| 158 | 23-Apr-25 | 54.42 | 55.49 | 51.95 | 53.02 | 12616 | 668886 |
| 159 | 22-Apr-25 | 52 | 57.99 | 51.16 | 54.11 | 12592 | 681393 |
| 160 | 21-Apr-25 | 50.7 | 52.69 | 50.7 | 51.54 | 8946 | 461083 |
| 161 | 17-Apr-25 | 52.8 | 52.8 | 51 | 51.77 | 7820 | 404816 |
| 162 | 16-Apr-25 | 52.84 | 53.49 | 51.8 | 52.56 | 5722 | 300723 |
| 163 | 15-Apr-25 | 50.5 | 53.9 | 50.5 | 52.34 | 7362 | 385331 |
| 164 | 11-Apr-25 | 50.25 | 51.5 | 49.3 | 50.13 | 3065 | 153636 |
| 165 | 09-Apr-25 | 51.48 | 51.48 | 48 | 49.16 | 6206 | 305076 |

| | | | | | | | |
|-----|-----------|-------|-------|-------|-------|--------|---------|
| 166 | 08-Apr-25 | 50 | 51.97 | 49.95 | 50.09 | 17724 | 887795 |
| 167 | 07-Apr-25 | 50 | 50.98 | 46.49 | 48.94 | 5914 | 289459 |
| 168 | 04-Apr-25 | 52.45 | 52.45 | 49.1 | 50.25 | 15571 | 782447 |
| 169 | 03-Apr-25 | 52.01 | 53.9 | 50.66 | 51.87 | 14541 | 754189 |
| 170 | 02-Apr-25 | 53.88 | 53.88 | 51.85 | 53.00 | 4493 | 238131 |
| 171 | 01-Apr-25 | 53.49 | 53.5 | 52.5 | 53.16 | 3396 | 180536 |
| 172 | 28-Mar-25 | 50.32 | 56 | 50.32 | 52.42 | 11903 | 623989 |
| 173 | 27-Mar-25 | 54.29 | 54.9 | 51 | 51.74 | 155519 | 8047036 |
| 174 | 26-Mar-25 | 55.56 | 55.56 | 51.5 | 53.66 | 16065 | 861983 |
| 175 | 25-Mar-25 | 59.2 | 59.5 | 55.9 | 56.65 | 60241 | 3412691 |
| 176 | 24-Mar-25 | 56.01 | 59 | 56.01 | 57.34 | 13385 | 767448 |
| 177 | 21-Mar-25 | 57 | 58.97 | 56.5 | 58.24 | 30330 | 1766334 |
| 178 | 20-Mar-25 | 55.97 | 58 | 55.9 | 57.32 | 14017 | 803432 |
| 179 | 19-Mar-25 | 53.1 | 55.95 | 53.1 | 55.40 | 4491 | 248795 |
| 180 | 18-Mar-25 | 53.24 | 55.88 | 50.71 | 54.10 | 19697 | 1065588 |
| 181 | 17-Mar-25 | 50.4 | 53 | 50.31 | 51.83 | 67178 | 3481752 |
| 182 | 13-Mar-25 | 51.98 | 51.98 | 48.5 | 49.85 | 40132 | 2000737 |
| 183 | 12-Mar-25 | 50.49 | 50.98 | 49.4 | 49.70 | 53749 | 2671443 |
| 184 | 11-Mar-25 | 53.6 | 53.6 | 47.99 | 49.96 | 13833 | 691028 |
| 185 | 10-Mar-25 | 55 | 55 | 51.41 | 52.94 | 54097 | 2863998 |
| 186 | 07-Mar-25 | 49.52 | 55.99 | 49.52 | 52.84 | 12896 | 681484 |
| 187 | 06-Mar-25 | 53.6 | 55.02 | 49.6 | 50.85 | 56359 | 2865760 |
| 188 | 05-Mar-25 | 49.37 | 50.68 | 49.37 | 50.28 | 9391 | 472212 |
| 189 | 04-Mar-25 | 45.34 | 52.97 | 42 | 46.31 | 98913 | 4580593 |
| 190 | 03-Mar-25 | 50 | 53.7 | 44.55 | 46.31 | 21507 | 996009 |
| 191 | 28-Feb-25 | 50.72 | 51.62 | 47 | 47.79 | 69364 | 3314765 |
| 192 | 27-Feb-25 | 56.5 | 56.5 | 48.05 | 51.55 | 5035 | 259560 |
| 193 | 25-Feb-25 | 54.99 | 55 | 52.35 | 53.64 | 40300 | 2161491 |
| 194 | 24-Feb-25 | 57.3 | 57.3 | 53.36 | 54.09 | 15180 | 821108 |
| 195 | 21-Feb-25 | 56.9 | 57.18 | 54 | 54.29 | 69446 | 3770284 |
| 196 | 20-Feb-25 | 56.5 | 56.5 | 53.52 | 55.03 | 3173 | 174603 |
| 197 | 19-Feb-25 | 51.25 | 55.2 | 51.25 | 53.80 | 13261 | 713450 |
| 198 | 18-Feb-25 | 50.05 | 52.97 | 48.8 | 50.74 | 99866 | 5067661 |
| 199 | 17-Feb-25 | 54.1 | 54.1 | 46 | 50.27 | 18508 | 930309 |
| 200 | 14-Feb-25 | 52 | 57 | 51.01 | 53.65 | 14921 | 800453 |
| 201 | 13-Feb-25 | 49.92 | 58.2 | 49.92 | 52.52 | 42560 | 2235409 |
| 202 | 12-Feb-25 | 49.59 | 50 | 44.99 | 47.33 | 36627 | 1733486 |
| 203 | 11-Feb-25 | 54.06 | 54.06 | 47.99 | 50.46 | 22570 | 1138954 |
| 204 | 10-Feb-25 | 57.39 | 57.39 | 52.52 | 54.24 | 16210 | 879208 |
| 205 | 07-Feb-25 | 57.3 | 57.3 | 56.3 | 56.77 | 713 | 40477 |
| 206 | 06-Feb-25 | 57 | 58.34 | 54.56 | 57.64 | 17160 | 989041 |
| 207 | 05-Feb-25 | 56 | 56 | 54.26 | 55.06 | 20607 | 1134523 |

| | | | | | | | |
|-----|-----------|-------|-------|-------|-------|-------|---------|
| 208 | 04-Feb-25 | 56.6 | 56.6 | 54.51 | 55.51 | 1628 | 90377 |
| 209 | 03-Feb-25 | 56.75 | 56.75 | 53.86 | 54.46 | 3063 | 166823 |
| 210 | 01-Feb-25 | 55.98 | 56.98 | 53.65 | 54.89 | 6403 | 351479 |
| 211 | 31-Jan-25 | 54 | 57 | 53.33 | 55.37 | 8730 | 483419 |
| 212 | 30-Jan-25 | 53.4 | 55.99 | 51.75 | 53.52 | 11035 | 590638 |
| 213 | 29-Jan-25 | 56.69 | 56.72 | 53.45 | 54.37 | 4689 | 254923 |
| 214 | 28-Jan-25 | 53.6 | 56.2 | 52.25 | 53.98 | 5818 | 314057 |
| 215 | 27-Jan-25 | 55.5 | 57.34 | 52.14 | 53.86 | 12072 | 650240 |
| 216 | 24-Jan-25 | 57.55 | 57.55 | 55.6 | 56.66 | 19162 | 1085673 |
| 217 | 23-Jan-25 | 55.85 | 57.2 | 55.28 | 56.84 | 2312 | 131409 |
| 218 | 22-Jan-25 | 56.27 | 57.19 | 55 | 56.38 | 4700 | 264974 |
| 219 | 21-Jan-25 | 57.85 | 57.85 | 55.5 | 55.80 | 23149 | 1291789 |
| 220 | 20-Jan-25 | 54.93 | 57.95 | 54.1 | 56.05 | 10575 | 592714 |
| 221 | 17-Jan-25 | 54.93 | 55.09 | 52.18 | 54.20 | 14788 | 801449 |
| 222 | 16-Jan-25 | 53.89 | 54.9 | 53.89 | 54.04 | 11655 | 629804 |
| 223 | 15-Jan-25 | 52.65 | 55.98 | 52.6 | 54.44 | 16766 | 912701 |
| 224 | 14-Jan-25 | 52 | 52.9 | 47.2 | 49.84 | 49914 | 2487506 |
| 225 | 13-Jan-25 | 55.11 | 55.11 | 51 | 52.03 | 52804 | 2747334 |
| 226 | 10-Jan-25 | 56.38 | 56.88 | 55 | 55.67 | 21285 | 1185016 |
| 227 | 09-Jan-25 | 57.75 | 58.7 | 55 | 56.51 | 27261 | 1540498 |
| 228 | 08-Jan-25 | 59.99 | 60.95 | 57 | 57.80 | 33729 | 1949597 |
| 229 | 07-Jan-25 | 61.14 | 62 | 59.3 | 60.01 | 41795 | 2508222 |
| 230 | 06-Jan-25 | 62.98 | 62.98 | 60 | 61.28 | 29078 | 1782013 |
| 231 | 03-Jan-25 | 62.44 | 63.45 | 61.38 | 62.31 | 6248 | 389288 |
| 232 | 02-Jan-25 | 62 | 62.6 | 60.56 | 61.59 | 7664 | 472012 |
| 233 | 01-Jan-25 | 61 | 64.9 | 60 | 61.72 | 41551 | 2564454 |
| 234 | 31-Dec-24 | 60.19 | 62.98 | 60 | 61.91 | 11693 | 723942 |
| 235 | 30-Dec-24 | 62.99 | 63.48 | 59.48 | 60.85 | 37760 | 2297863 |
| 236 | 27-Dec-24 | 63.99 | 63.99 | 61.22 | 62.77 | 9046 | 567808 |
| 237 | 26-Dec-24 | 66 | 66.89 | 59 | 62.24 | 40763 | 2537202 |
| 238 | 24-Dec-24 | 63.8 | 68.9 | 62.06 | 65.74 | 30905 | 2031787 |
| 239 | 23-Dec-24 | 67.01 | 67.01 | 60.3 | 63.30 | 24822 | 1571178 |
| 240 | 20-Dec-24 | 73 | 74.88 | 66 | 71.25 | 76823 | 5473894 |

| | |
|---|----------|
| Volume of Traded Shares | 4476584 |
| Total No. of Shares | 13720854 |
| % of Traded Turnover to Total No. of Shares | 32.63% |